DREAM3R – DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial

 

Trial Summary:

To determine the effectiveness of adding durvalumab to standard first line chemotherapy with cisplatin and pemetrexed in advanced pleural mesothelioma, and to identify potential and prognostic biomarkers from blood and tissue.

Supported By:

Astra Zeneca

Eligibility:

Adults commencing first-line systemic treatment for unresectable epithelioid pleural mesothelioma.

Registration ID:

NCT04334759

Participation:

Australia, New Zealand, USA

Status:

In follow-up

Activation Date:

3rd Feb 2021

Chairs:

Prof Anna Nowak

Contact:

dream3r.study@sydney.edu.au